Literature DB >> 589288

Saliva carbamazepine levels in children.

G W Rylance, G M Butcher, T Moreland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 589288      PMCID： PMC1632646          DOI： 10.1136/bmj.2.6100.1481

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  6 in total

1.  Anticonvulsant level in saliva, serum, and cerebrospinal fluid.

Authors:  A S Troupin; P Friel
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  Therapeutic monitoring of anticonvulsant drugs: gas-chromatographic simultaneous determination of primidone, phenylethylmalonamide, carbamazepine, and diphenylhydantoin.

Authors:  C J Least; G F Johnson; H M Solomon
Journal:  Clin Chem       Date:  1975-10       Impact factor: 8.327

Review 3.  Metabolism and Pharmacolinetics of Carbamazepine.

Authors:  P L Morselli; A Frigerio
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

4.  Salivary levels of anticonvulsants: a practical approach to drug monitoring.

Authors:  J J McAuliffe; A L Sherwin; I E Leppik; S A Fayle; C E Pippenger
Journal:  Neurology       Date:  1977-05       Impact factor: 9.910

5.  Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.

Authors:  A Rane; B Höjer; J T Wilson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

6.  Carbamazepine--a double-blind comparison with phenytoin.

Authors:  A Troupin; L M Ojemann; L Halpern; C Dodrill; R Wilkus; P Friel; P Feigl
Journal:  Neurology       Date:  1977-06       Impact factor: 9.910
  6 in total
  12 in total

1.  Measurement of saliva tacrolimus levels in pediatric renal transplant recipients.

Authors:  Vladimir Belostotsky; Jo Adaway; Brian G Keevil; Dena R Cohen; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2010-10-24       Impact factor: 3.714

2.  Clinical pharmacology. Drugs in children.

Authors:  G Rylance
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-03

3.  A comparison of plasma and saliva levels of carbamazepine and phenytoin as monotherapy.

Authors:  N Callaghan; T Goggin
Journal:  Ir J Med Sci       Date:  1984-05       Impact factor: 1.568

Review 4.  Drug level monitoring in paediatric practice.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

5.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

6.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

7.  Saliva carbamazepine levels in children before and during multiple dosing.

Authors:  T A Moreland; D A Priestman; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Carbamazepine 10,11-epoxide in children.

Authors:  G W Rylance; C Edwards; P R Gard
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

10.  Carbamazepine dose-frequency requirement in children.

Authors:  G W Rylance; T A Moreland; G M Butcher
Journal:  Arch Dis Child       Date:  1979-06       Impact factor: 3.791
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.